Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway

Li, Rong; Chen, Lu-Zhu; Zhao, Wang; Zhao, Shui‐Ping; Huang, Xiansheng

doi:10.1016/j.bbrc.2016.08.087

Cited by 16 publications

(23 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, TG accumulation in HepG2 cells induced by hyperglycemia and hyperinsulinemia were attenuated by metformin (3 mM) treatment [ 20 ]. Finally, hepatic and plasma TG in obese mice were also reduced by metformin treatment in a dose-dependent manner [ 21 , 22 ].…”

Section: Metformin Improves Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

“…The underlying mechanism of hepatic and plasma TG reduction following metformin treatment has been reported by several studies. Apolipoprotein A5 (ApoA5) plays a key role in regulating TG metabolism, particularly in the formation of lipid droplets in hepatocytes [ 22 ]. Significant elevation of plasma ApoA5 levels has been positively correlated with hepatocyte TG in obese mice [ 22 ].…”

Section: Metformin Improves Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

“…Apolipoprotein A5 (ApoA5) plays a key role in regulating TG metabolism, particularly in the formation of lipid droplets in hepatocytes [ 22 ]. Significant elevation of plasma ApoA5 levels has been positively correlated with hepatocyte TG in obese mice [ 22 ]. Four weeks of treatment with metformin (50 or 100 mg/kg) also reduces hepatocyte ApoA5 expression in obese mice [ 21 , 22 ].…”

Section: Metformin Improves Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

“…Significant elevation of plasma ApoA5 levels has been positively correlated with hepatocyte TG in obese mice [ 22 ]. Four weeks of treatment with metformin (50 or 100 mg/kg) also reduces hepatocyte ApoA5 expression in obese mice [ 21 , 22 ]. Interestingly, hepatic TG reduction induced by ApoA5 knockdown is further reduced by metformin treatment [ 22 ], suggesting the involvement of ApoA5 in metformin’s effect.…”

Section: Metformin Improves Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

“…Four weeks of treatment with metformin (50 or 100 mg/kg) also reduces hepatocyte ApoA5 expression in obese mice [ 21 , 22 ]. Interestingly, hepatic TG reduction induced by ApoA5 knockdown is further reduced by metformin treatment [ 22 ], suggesting the involvement of ApoA5 in metformin’s effect. Liver X receptor α (LXRα) is a transcription factor that plays an important role in the regulation of ApoA5 mRNA [ 22 ].…”

Section: Metformin Improves Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

See 4 more Smart Citations

Metformin: An Old Drug with New Applications

Zhou

Massey

Story

et al. 2018

IJMS

177

124

View full text Add to dashboard Cite

Metformin is a biguanide drug that has been used to treat type 2 diabetes mellitus for more than 60 years. The United Kingdom Prospective Diabetic Study (UKPDS) has shown metformin to improve mortality rates in diabetes patients, and recent studies suggest metformin has additional effects in treating cancer, obesity, nonalcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), and metabolic syndrome. Metformin has also been shown to alleviate weight gain associated with antipsychotic medication. Metformin has recently been extensively studied and emerging evidence suggests metformin decreases hepatocyte triglyceride accumulation in NAFLD and prevents liver tumorigenesis. Interestingly, studies have also shown metformin reduces visceral fat, suppresses white-adipose-tissue (WAT) extracellular matrix remodeling, and inhibits obesity-induced inflammation. However, clinical evidence for using metformin to treat NAFLD, cancer, metabolic syndrome, or to prevent hepatocellular carcinoma in NAFLD patients is lacking. This review therefore addresses the potential beneficial effects of metformin on NAFLD, its role in protecting against cardiac ischemia–reperfusion (I/R) injury, atherosclerosis, glucotoxicity, and lipotoxicity induced oxidative and ER stress in pancreatic β-cell dysfunction, as well as its underlying molecular mechanisms of action.

show abstract

Section: Metformin Improves Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

Section: Metformin Improves Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%